Skip to content
DataLookout
Menu

NCT07728188

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 3
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Trial sites reduced: 66 → 7 locations
    • Start date changed from estimate of Nov 30, 2026 to Oct 20, 2026
    • Secondary endpoints: details revised at 6 of 21 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety Run-In: Number of Participants With Adverse Events (AE)s
Timeframe: Up to Approximately 75 Months
Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment
Timeframe: Up to Approximately 75 Months
Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment
Timeframe: Up to Approximately 75 Months

Secondary (21)

Safety Run-In: Best Overall Response (BOR) of Per Investigator Assessment
Safety Run-In: Maximum Observed Concentration (Cmax) of Etentamig
Safety Run-In: Time to Cmax (Tmax) of Etentamig
Safety Run-In: Area under the Serum Concentration-Time Curve (AUC) of Etentamig
Safety Run-In: Immunogenicity of Etentamig
Show 16 moreShow less
Randomized Portion: Minimal Residual Disease Negative Complete Response (MRDnegCR) Per IRC Assessment
Randomized Portion: Overall Survival (OS)
Randomized Portion: Sustained Minimal Residual Disease (MRD) Negativity
Randomized Portion: Best Minimal Residual Disease Negative Complete Response (MRD Negative CR) Per IRC Assessment
Randomized Portion: BOR Per IRC Assessment
Randomized Portion: VGPR or Better Rate Per IRC Assessment
Randomized Portion: Time to Response (TTR) Per IRC Assessment
Randomized Portion: Duration of Response (DOR) Per IRC Assessment
Randomized Portion: Second Progression-Free Survival (PFS2)
Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (QoL) Score
Randomized Portion: Event-Free Survival (EFS) Per IRC Assessment
Randomized Portion: Time to Next Treatment (TTNT)
Randomized Portion: Time to Symptomatic Disease Progression
Randomized Portion: Change From Baseline in Disease Symptoms as Measured by the Disease Symptoms Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Myeloma Module (EORTC QLQ-MY20)
Randomized Portion: Change From Baseline in Physical Functioning as Measured by the Physical Functioning Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Randomized Portion: Overall Bother Due to Treatment Side Effects as Assessed by the Functional Assessment of Cancer Therapy - General Population, Item 5 (FACT-G GP5)

Arms and interventions

Safety Run-In: Etentamig Plus PomalidomideExperimental

Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.

Randomized Portion: Etentamig Plus PomalidomideExperimental

Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.

Randomized Portion: Standard Available Therapy (SAT)Active comparator

Participants will receive Investigator's choice of SATs: DPd, DKd, or teclistamab monotherapy as part of the 75 month study duration.

Drugs: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab

Sites

7 sites in 4 countries

Japan 4, Israel 1, Taiwan 1, United States 1